RxDoctor Payments Data

Lara Wynne

Nurse Practitioner · Montpelier, OHNPI 1336590660

Payments from drug & device makers

$1,282in general payments, 2019–2025

Across 66 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$403
  • AbbVie$194
  • Amgen$100
  • Merck$87
  • Exact Sciences$85
  • Boehringer Ingelheim$80
  • plus $332 from 9 others

What the payments were for

  • Food & beverage$1,282100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,282 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$66,288
Medicare patients
283
Services billed
1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$81,956
EliquisApixaban59$52,690
TrulicityDulaglutide31$44,868
OzempicSemaglutide25$27,467
MounjaroTirzepatide22$26,485
XareltoRivaroxaban32$24,394
TradjentaLinagliptin29$17,580
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,291
Spiriva RespimatTiotropium Bromide23$14,944
FarxigaDapagliflozin Propanediol12$14,658
Breo ElliptaFluticasone/Vilanterol37$13,114
Incruse ElliptaUmeclidinium Bromide23$8,027
PremarinEstrogens, Conjugated19$5,926
LinzessLinaclotide11$5,853
Albuterol Sulfate HfaAlbuterol Sulfate194$5,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$80$125,391171 claims
Lilly USA, LLCTrulicity, Mounjaro$76$71,35353 claims
AstraZenecaBreztri Aerosphere, Farxiga$403$29,94936 claims
Novo NordiskOzempic$33$27,46725 claims
GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta$46$25,53171 claims
AbbVieLinzess$194$5,85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Montpelier

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →